Literature DB >> 16394085

Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.

D S Kim1, J A Franklyn, A L Stratford, K Boelaert, J C Watkinson, M C Eggo, C J McCabe.   

Abstract

CONTEXT: Pituitary tumor-transforming gene (PTTG) is a multifunctional protein involved in several tumorigenic mechanisms, including angiogenesis. PTTG has been shown to promote angiogenesis, a key rate-limiting step in tumor progression, by up-regulation of fibroblast growth factor-2 and vascular endothelial growth factor.
OBJECTIVE: To investigate whether PTTG regulates other angiogenic genes in thyroid cells, we performed angiogenesis-specific cDNA arrays after PTTG transfection. Two of the genes [inhibitor of DNA binding-3 (ID3) and thrombospondin-1 (TSP-1)] which showed differential expression in primary thyroid cells were validated in vitro and in vivo.
RESULTS: TSP-1 showed a 2.5-fold reduction and ID3 showed a 3.5-fold induction in expression in response to PTTG overexpression in vitro. Conversely, suppression of PTTG with small interfering RNA was associated with a 2-fold induction of TSP-1 and a 2.2-fold reduction in ID3 expression. When we examined TSP-1 and ID3 expression in 34 differentiated thyroid cancers, ID3 was significantly increased in tumors compared with normal thyroid tissue. Furthermore, ID3 expression was significantly higher in follicular thyroid tumors than in papillary tumors. Although mean TSP-1 expression was not altered in cancers compared with normal thyroids, we observed a significant independent association between TSP-1 expression and early tumor recurrence, with recurrent tumors demonstrating 4.2-fold lower TSP-1 expression than normal thyroid tissues.
CONCLUSION: We have identified ID3 and TSP-1 as two new downstream targets of PTTG in thyroid cancer. We propose that PTTG may promote angiogenesis by regulating the expression of multiple genes with both pro- and antiangiogenic properties and may thus be a key gene in triggering the angiogenic switch in thyroid tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394085     DOI: 10.1210/jc.2005-1826

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins.

Authors:  Sudhakar Chintharlapalli; Sabitha Papineni; Syng-Ook Lee; Ping Lei; Un Ho Jin; Steven I Sherman; Libero Santarpia; Stephen Safe
Journal:  Mol Carcinog       Date:  2011-01-25       Impact factor: 4.784

2.  Pituitary tumor-transforming 1 expression in laryngeal cancer and its association with prognosis.

Authors:  Kunpeng Ma; Limin Ma; Zhaocheng Jian
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

3.  Pituitary tumor transforming gene binding factor: a new gene in breast cancer.

Authors:  Rachel J Watkins; Martin L Read; Vicki E Smith; Neil Sharma; Gary M Reynolds; Laura Buckley; Craig Doig; Moray J Campbell; Greg Lewy; Margaret C Eggo; Laurence S Loubiere; Jayne A Franklyn; Kristien Boelaert; Christopher J McCabe
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

4.  Association of PTTG1 polymorphism rs1895320, rs2910200 and rs6882742 with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Authors:  Bin Zhu; Ming Gao; Lei Zhang; Juan Wang; Lei Wang; Ling Ling Qin; Xi Xiong Kang; Zhi Gang Zhao
Journal:  Metab Brain Dis       Date:  2019-01-03       Impact factor: 3.584

5.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

6.  Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Tetsuo Ito; Yutaka Shimada; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Rachana Agarwal; Bogdan Paun; Zhe Jin; Alexandru Olaru; James P Hamilton; Jian Yang; John M Abraham; Stephen J Meltzer; Fumiaki Sato
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 7.  The pituitary tumor transforming gene in thyroid cancer.

Authors:  G D Lewy; N Sharma; R I Seed; V E Smith; K Boelaert; C J McCabe
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

8.  Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.

Authors:  S Hoffmann; S Gläser; A Wunderlich; S Lingelbach; C Dietrich; A Burchert; H Müller; M Rothmund; A Zielke
Journal:  Langenbecks Arch Surg       Date:  2006-10-12       Impact factor: 3.445

9.  Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin.

Authors:  Georges Said; Marie Guilbert; Hamid Morjani; Roselyne Garnotel; Pierre Jeannesson; Hassan El Btaouri
Journal:  Chemother Res Pract       Date:  2012-07-01

10.  Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck.

Authors:  Christine Solbach; Marc Roller; Frank Eckerdt; Silke Peters; Rainald Knecht
Journal:  BMC Cancer       Date:  2006-10-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.